Oricell Therapeutics Secures $110 Million Funding to Propel CAR-T Therapies for Solid Tumors Oricell Therapeutics has closed a significant pre-IPO funding round of over $110 million, aimed at accelerating global development of innovative CAR-T therapies targeting solid tumors.

Oricell Therapeutics Secures $110 Million Funding to Propel CAR-T Therapies for Solid Tumors #Shanghai #CAR-T_therapies #Oricell_Therapeutics #GPC3

Oricell Therapeutics Secures $70M to Propel CAR-T Therapy Development in Oncology Oricell Therapeutics, a leader in cancer immunotherapy, raises $70M in Series C funding to advance its CAR-T therapies for solid tumors.

Oricell Therapeutics Secures $70M to Propel CAR-T Therapy Development in Oncology #China #Shanghai #Cancer_Immunotherapy #CAR-T_therapy #Oricell_Therapeutics